{
  "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5",
  "docSlug": "adb5c4514a6016378ffb63c7d4422971",
  "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides",
  "authorId": "tcr2-therapeutics",
  "authorName": "TCR2 Therapeutics",
  "documentKindSlug": "regulatory-filing",
  "documentKindLabel": "Regulatory filing",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 34,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "other",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a process diagram to illustrate the dose escalation cohorts leading to the Recommended Phase 2 Dose (RP2D).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/15",
  "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5",
  "deckJsonHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5.json",
  "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.5,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "diagram",
      "text": "Dose escalation cohorts from Level 0 to Level 7 with corresponding cell doses",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a3ee6cde-af01-4967-891a-1a7e16f6e42f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.58,
        "y": 0.45
      },
      "kind": "list",
      "text": "Mesothelin Expression: IHC assay, Central lab (Roche/Ventana), Cut-off: ≥50% 2+/3+",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "856c3c9c-aadf-47e7-a568-e8bc35951db9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.58,
        "y": 0.25
      },
      "kind": "list",
      "text": "Indications: MPM, Ovarian cancer, NSCLC, Cholangiocarcinoma",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d4f3130a-4c7f-47e7-a016-064d87343598",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.58,
        "y": 0.65
      },
      "kind": "list",
      "text": "Lymphodepletion (LD): Fludarabine: 30 mg/m² x4d, Cyclophosphamide: 600 mg/m² x3d",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f86b67cf-15d5-4bd3-bd10-9b3d5314d84f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.03,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "(- LD) Cohorts = 1 patient; (+ LD) Cohorts = 3 patients",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35843ea5-026f-449e-aab7-c76532cafd48",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "gavo-cel Phase 1 Trial in MSLN+ Solid Tumors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68a2ab37-aebe-4135-ad90-83b784e83bf3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.58,
        "y": 0.18
      },
      "kind": "title",
      "text": "Phase 1: Dose Finding",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "98562186-b102-4dde-8c86-e236ccc52c61",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "600c504b-4bad-4cde-bbfd-6d6928df3bdf",
      "evidence": "The slide contains a list of bullet points describing the gavo-cel Phase 1 Trial in MSLN+ Solid Tumors.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 18,
      "from": 8,
      "beatId": "fd7bc9b8-ed02-40c1-b1d1-66cb54ef449d",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 15,
      "from": 15,
      "beatId": "4ca3c30c-a6d7-4c34-8a47-6147b35a76fc",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The document provides details on the Phase 1 trial in MSLN+ solid tumors.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 18,
      "from": 8,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "0a2012e0-6a06-4e15-803c-e8ae832be1d6",
      "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.",
      "position": 1,
      "objective": "How can TRuC-T cell therapy address the needs of patients with solid tumors?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}